Dengue is which infection

A doctor or nurse practitioner will examine you. He or she will ask you questions about how you're feeling, your medical history, and recent travels. Your doctor might want you to give a blood sample to test for the disease. If you've been diagnosed with dengue, call your doctor or get to a hospital emergency room right away if your symptoms get worse or if new symptoms appear, especially in the day or two after the fever goes down. For mild cases, doctors usually recommend drinking plenty of fluids to avoid dehydration, getting lots of rest, and taking acetaminophen to relieve the fever and pain.

People with dengue shouldn't take medicines with aspirin or ibuprofen, which can make bleeding more likely. Most cases of dengue fever will go away within a couple of weeks and won't cause any long-term problems. But dengue hemorrhagic fever requires treatment in a hospital with intravenous IV fluids and close monitoring. That's why it's really important to call a doctor or go to the ER if symptoms are severe or get worse in the first day or two after the fever goes away.

That's when dengue hemorrhagic fever is most likely to develop. You can help keep yourself free of dengue fever by avoiding mosquito bites. If you live in or will be visiting an area where there's dengue fever:. There is no vaccine against dengue fever yet. Because the infection is common in tropical and subtropical areas, take precautions when visiting those regions. Reviewed by: Steven Dowshen, MD. Larger text size Large text size Regular text size. What Is Dengue Fever?

After the fever goes down, they may notice these additional symptoms: nausea and vomiting severe abdominal pain difficulty breathing severe bleeding If dengue hemorrhagic fever is not treated right away, a person can have heavy bleeding and a drop in blood pressure, and could even die. In areas of the world where dengue fever is common, one dengue fever vaccine Dengvaxia is approved for people ages 9 to 45 who have already had dengue fever at least once.

The vaccine is given in three doses over the course of 12 months. The vaccine is approved only for people who have a documented history of dengue fever or who have had a blood test that shows previous infection with one of the dengue viruses — called seropositivity. In people who have not had dengue fever in the past seronegative , receiving the vaccine appears to increase the risk of severe dengue fever and hospitalization due to dengue fever in the future.

Dengvaxia is not available for travelers or for people who live in the continental United States. But in , the U. Food and Drug Administration approved the vaccine for people ages 9 to 16 who have had dengue fever in the past and who live in the U. Virgin Islands — where dengue fever is common. The World Health Organization stresses that the vaccine is not an effective tool on its own to reduce dengue fever in areas where the illness is common. Preventing mosquito bites and controlling the mosquito population are still the main methods for preventing the spread of dengue fever.

If you live in or travel to an area where dengue fever is common, these tips may help reduce your risk of mosquito bites:. Mayo Clinic does not endorse companies or products.

Advertising revenue supports our not-for-profit mission. This content does not have an English version. This content does not have an Arabic version. Overview Dengue DENG-gey fever is a mosquito-borne illness that occurs in tropical and subtropical areas of the world. Request an Appointment at Mayo Clinic. Share on: Facebook Twitter.

Show references AskMayoExpert. Viral hemorrhagic fever. Mayo Clinic; Centers for Disease Control and Prevention. Accessed Oct. Natl Acad. USA , — Kanai, R. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. Zhang, Y. Conformational changes of the flavivirus e glycoprotein. Structure 12 , — Roehrig, J. Antigenic structure of flavivirus proteins. Virus Res. Rey, F.

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Muller, D. The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Res. Akey, D. Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system. Science , — Mackenzie, J. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication.

Virology , — Libraty, D. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. Beatty, P. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Transl Med. The data presented in this article indicate that immunization with NS1 could provide crucial protection against severe dengue disease and argue for the inclusion in dengue vaccine.

Modhiran, N. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Marovich, M. Human dendritic cells as targets of dengue virus infection.

Johnston, L. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. Aye, K. Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Balsitis, S. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Durbin, A. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever.

Wu, S. Human skin Langerhans cells are targets of dengue virus infection. Miagostovich, M. Retrospective study on dengue fatal cases. Rosen, L. Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection. Couvelard, A. Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. Marianneau, P. Induction of programmed cell death apoptosis by dengue virus in vitro and in vivo.

Acta Cient. PubMed Google Scholar. Smit, J. Flavivirus cell entry and membrane fusion. Viruses 3 , — Sabin, A. Research on dengue during World War II. Montoya, M. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl. Fibriansah, G. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins.

Dengue virus. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science , 88—91 Wahala, W. The human antibody response to dengue virus infection.

Dejnirattisai, W. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Rouvinski, A. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Etiologies of the experimental dengues of Siler and Simmons. Epidemiologic studies on dengue in Santiago de Cuba, In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.

Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog.

Olkowski, S. Reduced risk of disease during postsecondary dengue virus infections. Gibbons, R. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Kliks, S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants.

Chau, T. Dengue in Vietnamese infants — results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. Clinical and virological features of Dengue in Vietnamese infants.

Observations related to pathogenesis of dengue hemorrhagic fever. Hypotheses and discussion. Yale J. Messer, W. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. Enhanced severity of secondary dengue-2 infections: death rates in and Cuban outbreaks.

Salud Publica 11 , — Hubert, B. Dengue 1 virus and dengue hemorrhagic fever, French Polynesia, Sangkawibha, N. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. The outbreak. Yauch, L. Zompi, S. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Weiskopf, D. USA , E—E Hanley, K. Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus. BMC Ecol. Bara, J. Susceptibility of larval Aedes aegypti and Aedes albopictus Diptera: Culicidae to dengue virus.

Rico-Hesse, R. Microevolution and virulence of dengue viruses. Dengue virus—mosquito interactions. Controversies in dengue pathogenesis. Child Health 32 Suppl. In this paper, six controversies in relation to the pathogenesis of dengue fever are analysed and, where possible, resolved. The Emperor's New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever.

Anderson, J. Aedes aegypti vectorial capacity is determined by the infecting genotype of dengue virus. Cologna, R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. Quantitative aspects of replication of dengue viruses in Aedes albopictus Diptera: Culicidae after oral and parenteral infection. Dietz, V.

The dengue and dengue hemorrhagic fever epidemic in Puerto Rico: epidemiologic and clinical observations. Health Sci. Bennett, S. Selection-driven evolution of emergent dengue virus. Steel, A. Natural attenuation of dengue virus type-2 after a series of island outbreaks: a retrospective phylogenetic study of events in the South Pacific three decades ago.

Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. Emergence and global spread of a dengue serotype 3, subtype III virus. Vaughn, D. Invited commentary: dengue lessons from Cuba. Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics?

Rodriguez-Roche, R. Virus role during intraepidemic increase in dengue disease severity. Vector Borne Zoonotic Dis. Chen, H. Evolution of dengue virus type 2 during two consecutive outbreaks with an increase in severity in southern Taiwan in — OhAinle, M. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Manokaran, G.

Dengue hemorrhagic fever in Cuba, a retrospective seroepidemiologic study. Sierra, B. Race: a risk factor for dengue hemorrhagic fever. Stephens, H. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 60 , — Falcon-Lezama, J. Acta Trop. Polizel, J. Association of human leukocyte antigen DQ1 and dengue fever in a white Southern Brazilian population.

Oswaldo Cruz 99 , — Appanna, R. Susceptible and protective HLA class 1 alleles against dengue fever and dengue hemorrhagic fever patients in a Malaysian population.

Loke, H. Lan, N. Perez, A. Soundravally, R. Garcia, G. Fernandez-Mestre, M. Tissue Antigens 64 , — Effect of age on outcome of secondary dengue 2 infections. Dengue and chikungunya virus infection in man in Thailand, — IV. Epidemiologic studies in the Bangkok metropolitan area.

Schlesinger, R. Gamble, J. Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock? Farrar, J. Book Google Scholar. Jessie, K. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization.

Bethell, D. Noninvasive measurement of microvascular leakage in patients with dengue hemorrhagic fever. Assessment of body fluid compartment volumes by multifrequency bioelectrical impedance spectroscopy in children with dengue. Kalayanarooj, S. Early clinical and laboratory indicators of acute dengue illness.

Wills, B. Size and charge characteristics of the protein leak in dengue shock syndrome. Mitrakul, C. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever.

Bleeding problem in dengue haemorrhagic fever: platelets and coagulation changes. Southeast Asian J. Public Health 18 , — Nelson, E. Hematologic findings in the hemorrhagic fever epidemic dengue in Thailand. Bierman, H. Hematodepressive virus diseases of Thailand. Binder, D. Bhamarapravati, N. Pathology of Thailand haemorrhagic fever: a study of autopsy cases. Krishnamurti, C. Mechanisms of hemorrhage in dengue without circulatory collapse.

Coagulation abnormalities in dengue hemorrhagic fever: serial investigations in Vietnamese children with dengue schock syndrome. Srikiatkhachorn, A. Plasma leakage in dengue haemorrhagic fever. Lin, S. Bokisch, V. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. The role of complement in hemorrhagic shock syndrome dengue.

Physicians 86 , — Cao, X. Evaluation of the World Health Organization standard tourniquet test and a modified tourniquet test in the diagnosis of dengue infection in Vietnam. Health 7 , — Chairulfatah, A. Hospital based clinical surveillance for dengue haemorrhagic fever in Bandung, Indonesia — Harris, E.

Clinical, epidemiologic and virologic features of dengue in the epidemic in Nicaragua. Nimmannitya, S. Dengue and chikungunya virus infection in man in Thailand, — Observations on hospitalized patients with hemorrhagic fever. Kabra, S. Dengue haemorrhagic fever in children in the Delhi epidemic. Nguyen, T. The impact of dengue haemorrhagic fever on liver function.

Mongkolsapaya, J. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Pang, T. Cell Biol. Rothman, A. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Russell, P. Immunopathological mechanisms in the dengue shock syndrome.

Article Google Scholar. Lin, Y. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Maywood , — Wan, S. Autoimmunity in dengue pathogenesis. St John, A. Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage. Carr, J. Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers.

Luplertlop, N. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep. MMP cellular responses to dengue virus infection-induced vascular leakage. Jpn J. A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections.

Michels, M. High plasma mid-regional pro-adrenomedullin levels in children with severe dengue virus infections. Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding.

Schlesinger, J. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. Dengue vascular permeability syndrome: what no T cells? Tang, K. Diagnosis of dengue: an update. Expert Rev. Anti Infect. Hunsperger, E. Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Vazquez, S. Evaluation of immunoglobulin M and G capture enzyme-linked immunosorbent assay Panbio kits for diagnostic dengue infections.

Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody. Dengue: a continuing global threat. Dengue and severe dengue. Punyadee, N. Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection. Yacoub, S. Dengue: an update for clinicians working in non-endemic areas. The predictive diagnostic value of serial daily bedside ultrasonography for severe dengue in Indonesian adults.

Potts, J. Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations.

Health 13 , — Prediction of dengue disease severity among pediatric Thai patients using early clinical laboratory indicators. Huang, S. Use of simple clinical and laboratory predictors to differentiate influenza from dengue and other febrile illnesses in the emergency room.

BMC Infect. Horstick, O. Comparing the usefulness of the and WHO dengue case classification: a systematic literature review. Dogma in classifying dengue disease. In this paper, a group of international dengue experts explain the main advantages of the revised classification of dengue, both for clinicians and epidemiologists and also for future research. Basuki, P. Application of revised dengue classification criteria as a severity marker of dengue viral infection in Indonesia. Public Health 41 , — Narvaez, F.

Evaluation of the traditional and revised WHO classifications of dengue disease severity. Zakaria, Z. An evaluation of the World Health Organization's and dengue classifications in hospitalized dengue patients in Malaysia. Ctries 8 , — Prasad, D. Accuracy and applicability of the revised WHO classification of dengue in children seen at a tertiary healthcare facility in Northern India. Infection 41 , — Evaluation of the WHO dengue case classification in an Indonesian pediatric cohort.

Lovera, D. Prospective applicability study of the new dengue classification system for clinical management in children. Gibson, G. From primary care to hospitalization: clinical warning signs of severe dengue fever in children and adolescents during an outbreak in Rio de Janeiro, Brazil.

Saude Publica 29 , 82—90 in Portuguese Pamplona, L. Oswaldo Cruz , 93—98 WHO dengue case classification and its usefulness in practice: an expert consensus in the Americas. Health , 19—25 Thein, T. Utilities and limitations of the World Health Organization warning signs for adult dengue severity.

Premaratna, R. Timing, predictors, and progress of third space fluid accumulation during preliminary phase fluid resuscitation in adult patients with dengue. Hadinegoro, S. The revised WHO dengue case classification: does the system need to be modified? Chaterji, S. Evaluation of the NS1 rapid test and the WHO dengue classification schemes for use as bedside diagnosis of acute dengue fever in adults.

Gan, V. Implications of discordance in World Health Organization and dengue classifications in adult dengue. Jaenisch, T. Dengue research funded by the European Commission — scientific strategies of three European dengue research consortia. Martinez-Torres, E. Preventing deaths from dengue: a space and challenge for primary health care. Salud Publica 20 , 60—74 in Spanish Recent advances in dengue pathogenesis and clinical management. Vaccine 33 , — Dengue hemorrhagic fever: the sensitivity and specificity of the world health organization definition for identification of severe cases of dengue in Thailand, — Akbar, N.

Murrell, S. Review of dengue virus and the development of a vaccine. Dengue virus vaccine development. This review discusses the adaptive immune response to DENV, dengue vaccine challenges, animal models used to test dengue vaccine candidates and historical and current dengue vaccine approaches. Villar, L.